{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T15:51:30Z","timestamp":1777909890126,"version":"3.51.4"},"reference-count":25,"publisher":"SAGE Publications","issue":"3","license":[{"start":{"date-parts":[[2019,4,1]],"date-time":"2019-04-01T00:00:00Z","timestamp":1554076800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2019,4,1]],"date-time":"2019-04-01T00:00:00Z","timestamp":1554076800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Journal of Ocular Pharmacology and Therapeutics"],"published-print":{"date-parts":[[2019,4,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Purpose:<\/jats:title>\n                    <jats:p>To compare the dose\u2013response profiles of bimatoprost sustained-release implant (Bimatoprost SR) and topical bimatoprost in lowering intraocular pressure (IOP) in normotensive beagle dogs.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>In 1 study, topical bimatoprost 0.001%, 0.01%, or 0.1% was administered twice daily in the study eye for 5 days. IOP was measured at baseline and up to hour 6 each day. Other studies evaluated the IOP response to a single administration of Bimatoprost SR at dose strengths ranging from 8 to 120\u2009\u03bcg. IOP was measured before implant administration and during 3 months of follow-up; IOP in response to topical bimatoprost 0.03% was measured prestudy as an internal control.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>Mean percentage decrease in IOP from baseline at hour 6 (peak effect) across study days was 15.7%, 36.1%, and 24.8% (2.8, 7.0, and 4.0\u2009mmHg) in animals treated with topical bimatoprost 0.001%, 0.01%, and 0.1%, respectively. After Bimatoprost SR administration, mean percentage decrease in IOP from baseline across 3 months consistently increased with increasing dose strength and was 38.7% (7.2\u2009mmHg) with Bimatoprost SR 120\u2009\u03bcg. Mean percentage IOP decrease with topical bimatoprost 0.03% was 27.6% (5.9\u2009mmHg).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>Topical bimatoprost demonstrated a U-shaped dose\u2013response curve; increasing the bimatoprost concentration to 0.1% resulted in reduced IOP-lowering efficacy. In contrast, the dose\u2013response curve for Bimatoprost SR showed consistently greater IOP lowering as the dose strength increased, with the dose strength producing maximum IOP lowering not yet determined. At 60- and 120-\u03bcg dose strengths, Bimatoprost SR produced greater IOP reductions than were achieved with topical dosing.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1089\/jop.2018.0095","type":"journal-article","created":{"date-parts":[[2019,1,30]],"date-time":"2019-01-30T10:41:40Z","timestamp":1548844900000},"page":"138-144","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":40,"title":["Dose\u2013Response of Intracameral Bimatoprost Sustained-Release Implant and Topical Bimatoprost in Lowering Intraocular Pressure"],"prefix":"10.1177","volume":"35","author":[{"given":"Susan S.","family":"Lee","sequence":"first","affiliation":[{"name":"Allergan plc, Irvine, California."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohammed","family":"Dibas","sequence":"additional","affiliation":[{"name":"Allergan plc, Irvine, California."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexandra","family":"Almazan","sequence":"additional","affiliation":[{"name":"Allergan plc, Irvine, California."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael R.","family":"Robinson","sequence":"additional","affiliation":[{"name":"Allergan plc, Irvine, California."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2019,4,6]]},"reference":[{"key":"e_1_3_3_2_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2016.04.031"},{"key":"e_1_3_3_3_2","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-017-0593-9"},{"key":"e_1_3_3_4_2","doi-asserted-by":"publisher","DOI":"10.1185\/03007995.2011.613923"},{"key":"e_1_3_3_5_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2015.09.005"},{"issue":"4","key":"e_1_3_3_6_2","first-page":"S361","article-title":"for the Bimatoprost Study Groups 1 and 2","volume":"45","author":"Sherwood M.","year":"2001","unstructured":"Sherwood M., , Brandt J.; for the Bimatoprost Study Groups 1 and 2. Six-month comparison of bimatoprost once-daily and twice-daily with timolol twice-daily in patients with elevated intraocular pressure. Surv. Ophthalmol. 45(Suppl 4):S361\u2013S368, 2001.","journal-title":"Six-month comparison of bimatoprost once-daily and twice-daily with timolol twice-daily in patients with elevated intraocular pressure. Surv. Ophthalmol"},{"key":"e_1_3_3_7_2","doi-asserted-by":"publisher","DOI":"10.2147\/OPTH.S143428"},{"key":"e_1_3_3_8_2","doi-asserted-by":"publisher","DOI":"10.1080\/02713689808951229"},{"key":"e_1_3_3_9_2","first-page":"1305","article-title":"Intraocular pressure-reducing effect of PhXA41 in ocular hypertension","volume":"100","author":"Nagasubramanian S.","year":"1993","unstructured":"Nagasubramanian S., , Sheth G.P., , Hitchings R.A., , and Stjernschantz J. Intraocular pressure-reducing effect of PhXA41 in ocular hypertension. Comparison of dose regimens. Ophthalmology. 100:1305\u20131311, 1993.","journal-title":"Comparison of dose regimens. Ophthalmology"},{"key":"e_1_3_3_10_2","first-page":"1312","article-title":"Intraocular pressure-reducing effect of PhXA41 in patients with increased eye pressure","volume":"100","author":"Alm A.","year":"1993","unstructured":"Alm A., , Villumsen J., , Tornquist P., et al. Intraocular pressure-reducing effect of PhXA41 in patients with increased eye pressure. A one-month study. Ophthalmology. 100:1312\u20131316, 1993.","journal-title":"A one-month study. Ophthalmology"},{"key":"e_1_3_3_11_2","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2415-12-9"},{"key":"e_1_3_3_12_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajo.2016.11.020"},{"key":"e_1_3_3_13_2","doi-asserted-by":"publisher","DOI":"10.1007\/s11095-010-0159-x"},{"key":"e_1_3_3_14_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1463-5216.2001.00201.x"},{"key":"e_1_3_3_15_2","doi-asserted-by":"publisher","DOI":"10.1089\/108076802321021072"},{"key":"e_1_3_3_16_2","doi-asserted-by":"publisher","DOI":"10.1111\/vop.12522"},{"key":"e_1_3_3_17_2","doi-asserted-by":"publisher","DOI":"10.1292\/jvms.68.631"},{"key":"e_1_3_3_18_2","doi-asserted-by":"publisher","DOI":"10.1007\/s11095-014-1311-9"},{"key":"e_1_3_3_19_2","doi-asserted-by":"publisher","DOI":"10.1111\/vop.12341"},{"key":"e_1_3_3_20_2","first-page":"12","article-title":"Glaucoma opinion: episcleral venous pressure","volume":"16","author":"Sit A.","year":"2015","unstructured":"Sit A. Glaucoma opinion: episcleral venous pressure. Int. Glaucoma Rev. 16:12\u201315, 2015.","journal-title":"Int. Glaucoma Rev"},{"key":"e_1_3_3_21_2","doi-asserted-by":"publisher","DOI":"10.1089\/jop.2014.0146"},{"key":"e_1_3_3_22_2","doi-asserted-by":"publisher","DOI":"10.1089\/jop.2017.0138"},{"key":"e_1_3_3_23_2","article-title":"Intracameral sustained-release bimatoprost implant delivers bimatoprost to target tissues with reduced drug exposure to off-target tissues","author":"Seal J.R.","year":"2018","unstructured":"Seal J.R., , Robinson M.R., , Burke J., , Bejanian M., , Coote M., , and Attar M. Intracameral sustained-release bimatoprost implant delivers bimatoprost to target tissues with reduced drug exposure to off-target tissues. J. Ocul. Pharmacol. Ther. 2018. [Epub ahead of print]; doi: 10.1089\/jop.2018.0067.","journal-title":"J. Ocul. Pharmacol. Ther"},{"key":"e_1_3_3_24_2","doi-asserted-by":"publisher","DOI":"10.1167\/iovs.02-1281"},{"key":"e_1_3_3_25_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0039-6257(97)80008-2"},{"key":"e_1_3_3_26_2","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-019-01248-0"}],"container-title":["Journal of Ocular Pharmacology and Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1089\/jop.2018.0095","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1089\/jop.2018.0095","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1089\/jop.2018.0095","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T14:42:49Z","timestamp":1777646569000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1089\/jop.2018.0095"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,4,1]]},"references-count":25,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2019,4,1]]}},"alternative-id":["10.1089\/jop.2018.0095"],"URL":"https:\/\/doi.org\/10.1089\/jop.2018.0095","relation":{},"ISSN":["1080-7683","1557-7732"],"issn-type":[{"value":"1080-7683","type":"print"},{"value":"1557-7732","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,4,1]]}}}